Streetbeat News

Regulatory

MLCO

Melco shares are trading lower after Sam Hou-Fai was elected as Macau's next leader. He has called for diversifying Macau's industries beyond gambling, which could impact Melco's operations.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:17 pm

SPY

Federal Reserve's Neel Kashkari emphasizes the importance of credibility and indicates that the economy is nearing the final stages of reducing inflation to 2%. The monetary policy remains restrictive, and the job market is strong. Modest rate cuts may be appropriate, with future policy driven by data.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:13 pm

PEN

Penumbra, Inc. has completed enrollment for its THUNDER IDE study, which evaluates the safety and efficacy of its latest thrombectomy technology for acute ischemic stroke treatment.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:04 pm

BABA

BIDU

JD

NIO

PDD

XPEV

U.S.-listed Chinese stocks, including Alibaba, Baidu, JD.com, PDD Holdings, NIO, and XPeng, are trading lower as China's recent stimulus measures failed to meet market expectations. The lack of specific figures for the stimulus has left investors anxious, contributing to the decline.

Portfolio Pulse from Anusuya Lahiri

October 14, 2024 | 12:52 pm

NIVF

NewGenIvf shares declined following a noncompliance notification from Nasdaq, indicating potential issues with listing requirements.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 12:51 pm

STLA

Stellantis CEO Carlos Tavares stated that Chinese carmakers are unlikely to produce cars in Germany, France, or Italy due to cost disadvantages, particularly energy costs. He also mentioned that EU duties on Chinese EVs could lead to accelerated plant closures by European automakers.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 12:47 pm

BYDDF

BYDDY

BYD criticized the EU's proposed tariffs on Chinese-made EVs at the Paris Car Show, warning of increased costs and market impact. The tariffs aim to counter alleged unfair subsidies from China, but have sparked debate and concerns over trade tensions.

Portfolio Pulse from Benzinga Neuro

October 14, 2024 | 12:45 pm

GSK

GSK's phase 3 trials for depemokimab show promising results in reducing nasal polyp size and nasal obstruction in patients with chronic rhinosinusitis. The trials met their primary endpoints, and further data analysis is ongoing. GSK's stock is up 0.80% in premarket trading.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 12:39 pm

BLCO

Bausch + Lomb shares rose following FDA approval of their enVista Envy product.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 12:19 pm

STSS

Sharps Technology announced a 1-for-22 reverse stock split effective October 15, 2024, to comply with Nasdaq's minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 12:19 pm